Leukotrienes and Other Lipoxygenase Products in the Pathogenesis and Therapy of Psoriasis and Other DermatosesVoorhees, John J.
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310003001
Abstract In this issue of the Archives (page 548), Kragballe and Herlin describe a double-blind study that clearly demonstrates that benoxaprofen is efficacious in the therapy of psoriasis. This exciting observation may have a substantial impact on drug development for psoriasis and possibly other inflammatory proliferative skin diseases. My purpose is to present evidence that has caused me to conclude that the observations of Kragballe and Herlin are of unusual importance. This evidence will be understood best if it is presented in the context of current information on arachidonic acid (AA) transformations in the epidermis and in whole skin. AA TRANSFORMATIONS Arachidonic acid, an unsaturated fatty acid, is the precursor of prostaglandins (PGs), hydroxyeicosatetraenoic acids (HETEs), thromboxanes (TXs), and leukotrienes (LTs).1 The backbone of lecithin is glycerol with its three carbon atoms. Arachidonic acid is esterified to the middle (the so-called 2 position) of these three atoms in epidermal lecithin References 1. Samuelsson B: Leukotrienes: Mediators of allergic reactions and inflammation . Int Arch Allergy Appl Immunol 1981;66( (suppl 1) ):98-106.Crossref 2. Gurr MI, James AT: Lipid Biochemistry: An Introduction , ed 3. New York, Chapman and Hall, 1980, p 3. 3. Ziboh VA, Lord JT: Phospholipase A activity in the skin: Modulators of arachidonic acid release from phosphatidylcholine . Biochem J 1979;184:283-290. 4. Greaves MW: Prostaglandins and dermatology . J R Coll Physicians Lond 1982;16:219-225. 5. Gurr MI, James AT: Lipid Biochemistry: An Introduction . New York, Chapman and Hall, 1980, p 216. 6. Hammarström S, Hamberg M, Samuelsson B, et al: Increased concentrations of nonesterified arachidonic acid, 12-L-hydroxy5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2α in epidermis of psoriasis . Proc Natl Acad Sci USA 1975;72:5130-5134.Crossref 7. Hammarström S, Lindgren JA, Marcelo C, et al: Arachidonic acid transformations in normal and psoriatic skin . J Invest Dermatol 1979;73:180-183.Crossref 8. Black AK, Fincham N, Greaves MW, et al: Time course changes in levels of arachidonic acid and prostaglandins D2, E2, F2α in human skin following ultraviolet B irradiation . Br J Clin Pharmacol 1980;10:453-457.Crossref 9. Oikarinen A, Viinikka L, Rytsala H, et al: Prostacyclin, thromboxane and prostaglandin F2α in suction blister fluid of human skin: Effect of systemic aspirin and local glucocorticosteroid treatment . Life Sci 1981;29:391-396.Crossref 10. Ziboh VA, Marcelo CL, Voorhees JJ: Induced lipoxygenation of arachidonic acid in mouse epidermal keratinocytes by calcium ionophore A23187 , abstracted. J Invest Dermatol 1981;76:307. 11. Brain SD, Camp RD, Leigh IM, et al: The synthesis of leukotriene B4-like material by cultured human keratinocytes, abstracted . J Invest Dermatol 1982;78:328. 12. Ziboh VA, Casebolt T, Marcelo CL, et al: Lipoxygenation of arachidonic acid by subcellular preparations from murine keratinocytes , abstracted. Clin Res , in press. 13. Eaglstein WH, Weinstein GD: Prostaglandin and DNA synthesis in human skin: Possible relationship to ultraviolet light effects . J Invest Dermatol 1975;64:386-389.Crossref 14. Lowe NJ, Stoughton RB: Effects of topical prostaglandin E2 analogue on normal hairless mouse epidermal DNA synthesis . J Invest Dermatol 1977;68:134-137.Crossref 15. Furstenberger G, Marks F: Early prostaglandin E synthesis is an obligatory event in the induction of cell proliferation in mouse epidermis in vivo by the phorbol ester TPA . Biochem Biophys Res Commun 1980;92:749-756.Crossref 16. Furstenberger G, de Bravo M, Bertsch S, et al: The effect of indomethacin on cell proliferation induced by chemical and mechanical means in mouse epidermis in vivo . Res Commun Chem Pathol Pharmacol 1979;24:533-541. 17. Marks F, Furstenberger G, Kownatzki E: Prostaglandin E-mediated mitogenic stimulation of mouse epidermis in vivo by divalent cation ionophore A23187 and by tumor promoter 12- 0-tetradecanoylphorbol-13-acetate . Cancer Res 1981;41:696-702. 18. Delescluse C, Furstenberger G, Marks F, et al: Effects of phorbol esters on basal epidermal cells derived from ear skin of adult guinea pigs . Cancer Res 1982;42:1975-1979. 19. Bokoch GM, Reed PW: Evidence for inhibition of leukotriene A4 synthesis by 5,8,11,14-eicosatetraynoic acid in guinea pig polymorphonuclear leukocytes . J Biol Chem 1981;256:4156-4159. 20. Kelly JP, Johnson MC, Parker CW: Effect of inhibitors of arachidonic acid metabolism on mitogenesis in human lymphocytes: Possible role of thromboxanes and products of the lipoxygenase pathway . J Immunol 1979;122:1563-1571. 21. Bailey JM, Bryant RW, Low CE, et al: Regulation of T-lymphocyte mitogenesis by the leukocyte product 15-hydroxyeicosatetraenoic acid (15-HETE) . Cell Immunol 1982;67:112-120.Crossref 22. Bailey DM, Casey FB: Lipoxygenase and the related arachidonic acid metabolites , in Annual Reports in Medicinal Chemistry . New York, Academic Press Inc, 1982 vol 17, pp 203-217. 23. Penneys NS, Simon P, Ziboh VA, et al: In vivo chemotaxis induced by polyunsaturated fatty acids . J Invest Dermatol 1977;69:435-438.Crossref 24. Goetzl EJ, Woods JM, Gorman RR: Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid . J Clin Invest 1977;59:179-183.Crossref 25. Lewis RA, Soter NA, Corey EJ, et al: The effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human (H) skin . J Invest Dermatol 1983;80:115-119.Crossref 26. Carr SC, Higgs GA, Salmon JA, et al: The effects of arachidonate lipoxygenase products on leukocyte migration in rabbit skin . Br J Pharmacol 1981;73:253-254. 27. Bisgaard H, Kristensen J, Sondergaard J: The effect of leukotriene C, and D, on cutaneous blood flow in humans . Prostaglandins 1982;23:797-801.Crossref 28. Dahlen SE, Bjork J, Hedqvist P, et al: Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: In vivo effects with relevance to the acute inflammatory response . Proc Natl Acad Sci USA 1981;78:3887-3891.Crossref 29. Plummer NA, Hensby CN, Warin AP, et al: Prostaglandins E2, F2α and arachidonic acid levels in irradiated and unirradiated skin of psoriatic patients receiving PUVA treatment . Clin Exper Dermatol 1978;3:367-369.Crossref 30. Penneys N, Ziboh V, Lord J, et al: Inhibitor(s) of prostaglandin synthesis in psoriatic plaque . Nature 1975;254:351-352.Crossref 31. Shier WT: Inhibition of prostaglandin synthesis by lysolecithin . Biochem Biophys Res Commun 1977;78:1168-1174.Crossref 32. Brain S, Camp R, Dowd P, et al: Psoriasis and leukotriene B4 . Lancet 1982;2:762-763.Crossref 33. Ziboh VA, Casebolt T, Marcelo CL, et al: Enhancement of 5-lipoxygenase activity in soluble preparations of human psoriatic plaque preparation , abstracted. J Invest Dermatol , in press. 34. Grabbe J, Czarnetzki BM, Mardin M: Chemotactic leukotrienes in psoriasis . Lancet 1982;2:1464.Crossref 35. Maclouf J, Fruteau de Laclos B, Borgeat P: Stimulation of leukotriene biosynthesis in human blood leukocytes by plateletderived 12-hydroperoxy-eicosatetraenoic acid . Proc Natl Acad Sci USA 1982;79:6042-6046.Crossref 36. Farber EM, Roth RJ, Aschheim E, et al: Role of trauma in isomorphic response in psoriasis . Arch Dermatol 1965;91:246-251.Crossref 37. Katayama H, Kawada A: Exacerbation of psoriasis induced by indomethacin . J Dermatol 1981;8:323-337. 38. Ellis CN, Fallon JD, Heezen JL, et al: Topical indomethacin exacerbates lesions of psoriasis . J Invest Dermatol , in press. 39. Dawson W, Boot JR, Harvey J, et al: The pharmacology of benoxaprofen with particular reference to effects on lipoxygenase product formation . Eur J Rheumatol Inflam 1982;5:61-68. 40. Lee VY, Hughes JM, Seale JP, et al: Effect of benoxaprofen on release of slow-reacting substances from human lung tissue in vitro . Clin Sci 1982;63:219-221. 41. Higgs GA, Flower RJ: Anti-inflammatory drugs and the inhibition of arachidonate lipoxygenase , in Piper PJ (ed): SRS-A and Leukotrienes . New York, John Wiley & Sons Inc, 1981, pp 197-207. 42. Allen BR, Littlewood SM: Benoxaprofen: Effect on cutaneous lesions in psoriasis . Br Med J 1982;285:1241.Crossref 43. Kingston T, Marks R: Benoxaprofen: Effect on cutaneous lesions in psoriasis . Br Med J 1982;285:1741.Crossref 44. Hindson C, Lawlor F, Wacks H: Benoxaprofen for nodular acne . Lancet 1982;1:1415.Crossref 45. Hindson C, Lawlor F, Wacks H: Treatment of nodular prurigo with benoxaprofen . Br J Dermatol 1982;107:369-372.Crossref 46. Fenton DA, Wilkinson JD: Benoxaprofen: Effect on cutaneous lesions in psoriasis . Br Med J 1982;285:1420-1421.Crossref 47. Baumann J, Bruchhausen F, Wurm G: Flavonoids and related compounds as inhibitors of arachidonic acid peroxidation . Prostaglandins 1980;20:627-639.Crossref 48. Sok D, Han C, Pai J, et al: Inhibition of leukotriene biosynthesis by acetylenic analogs . Biochem Biophys Res Commun 1982;107:101-108.Crossref 49. Smith RJ, Sun FF, Bowman BJ, et al: Effect of 6,9-deepoxy-6,9-(phenylimino)-Δ6,8 prostaglandin I, (U-60,257), an inhibitor of leukotriene synthesis, on human neutrophil function . Biochem Biophys Res Commun 1982;109:943-949.Crossref 50. Radmark O, Malmsten C, Samuelsson B: The inhibitory effects of BW 755C on arachidonic acid metabolism in human polymorphonuclear leukocytes . FEBS Lett 1980;110:213-215.Crossref 51. Ahnfelt-Ronne I, Arrigoni-Martelli E: Multiple effects of a new anti-inflammatory agent, timegadine, on arachidonic acid release and metabolism in neutrophils and platelets . Biochem Pharmacol 1982;31:2619-2624.Crossref 52. Koshishara Y, Murota S, Petasis NA, et al: Selective inhibition of 5-lipoxygenase by 5,6-methanoleukotriene A4, a stable analogue of leukotriene A4 . FEBS Lett 1982;143:13-16.Crossref 53. Yoshimoto T, Yokoyama C, Ochi K, et al: 2,3,5-Trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone (AA 861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis of slow-reacting substance of anaphylaxis . Biochim Biophys Acta 1982;713:470-473.Crossref 54. Strauss JS, Pochi PE, Whitman EN: Suppression of sebaceous gland activity with eicosa-5:8:11:14-tetraynoic acid . J Invest Dermatol 1967;48:492-493. 55. Penneys NS: Inhibition of arachidonic acid oxidation in vitro by vehicle components . Acta Derm Venereol 1982;62:59-61. 56. Hammarström S, Hamberg M, Duell EA, et al: Glucocorticoid in inflammatory proliferative skin disease reduces arachidonic and hydroxyeicosatetraenoic acids . Science 1977;197:994-996.Crossref 57. Black AK, Greaves MW, Hensby CN: The effect of systemic prednisolone on arachidonic acid, and prostaglandin E2 and F2α levels in human cutaneous inflammation . Br J Clin Pharmacol 1982;14:391-394.Crossref 58. Hirata F, del Carmine R, Nelson CA, et al: Presence of autoantibody for phospholipase inhibitory protein lipomodulin, in patients with rheumatic diseases . Proc Natl Acad Sci USA 1981;78:3190-3194.Crossref 59. Blackwell GJ, Carnuccio R, Di Rosa M, et al: Macrocortin: A polypeptide causing the anti-phospholipase effect of glucocorticoids . Nature 1980;287:147-149.Crossref 60. Scholkens BA, Gehring D, Schlotte V, et al: Evening primrose oil, a dietary prostaglandin precursor, diminishes vascular reactivity to renin and angiotensin II in rats . Prostaglandins Leukotrienes Med 1982;8:273-285.Crossref 61. Needleman SW, Spector AA, Hoak JC: Enrichment of human platelet phospholipids with linoleic acid diminishes thromboxane release . Prostaglandins 1982;24:607-622.Crossref 62. Gurr MI, James AT: Lipid Biochemistry: An Introduction . New York, Chapman and Hall, 1982, pp 52-53. 63. Willis AL: Nutritional and pharmacological factors in eicosanoid biology . Nutr Rev 1981;39:289-301.Crossref 64. Wright S, Burton JL: Oral evening primrose seed oil improves atopic eczema . Lancet 1982;2:1120-1122.Crossref 65. Hammarström S: Leukotriene C5: A slow reacting substance derived from eicosapentaenoic acid . J Biol Chem 1980;255:7093-7094. 66. Prickett JD, Robinson DR, Steinberg AD: Dietary enrichment with the polyunsaturated fatty acid eicosapentaenoic acid prevents proteinuria and prolongs survival in NZB X NZW F, mice . J Clin Invest 1981;68:556-559.Crossref 67. Hellgren L: Psoriasis . Uppsala, Sweden, Almqvist & Wiksell, 1967, p 19. 68. Voorhees JJ: Commentary: Cyclic adenosine monophosphate regulation of normal and psoriatic epidermis . Arch Dermatol 1982;118:869-874.Crossref
Benoxaprofen Improves Psoriasis: A Double-blind StudyKragballe, Knud;Herlin, Troels
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310010002
Abstract • The pathophysiologic significance of increased levels of lipoxygenase compounds in psoriatic lesions was assessed in a double-blind randomized clinical study with the 5-lipoxygenase inhibitor, benoxaprofen. Forty patients with psoriasis vulgaris were treated with 600 mg of oral benoxaprofen daily or a placebo for a period of eight weeks. Benoxaprofen therapy provided excellent treatment results in about 75% of the cases. In the placebo group, only minimal improvement occurred. Most patients receiving benoxaprofen therapy reported side effects including photosensitivity, onycholysis, milia, diarrhea, and edema. In two cases, benoxaprofen was withdrawn before completion of the treatment course because of photosensitivity. Benoxaprofen may affect psoriatic epidermis either directly by the inhibition of epidermal 5-lipoxygenase or indirectly by the inhibition of the accumulation of phagocytes in psoriatic lesions. Despite serious side effects from benoxaprofen therapy, lipoxygenase-inhibiting agents deserve further study in the treatment of psoriasis. (Arch Dermatol 1983;119:548-552) References 1. Hammarstrom S, Hamberg M, Samuelsson B, et al: Increased concentrations of nonesterified arachidonic acid, 12-L-hydroxy-5,8,14-eicosatetraenoic acid, prostaglandin E2, prostaglandin F2α in epidermis of psoriasis . Proc Natl Acad Sci USA 1975;72:5130-5134.Crossref 2. Samuelsson B, Goldyne M, Granstrom E, et al: Prostaglandins and thromboxanes . Annu Rev Biochem 1971;47:997-1029.Crossref 3. Borgeat P, Samuelsson B: Arachidonic acid metabolism in polymorphonuclear leukocytes: Effects of ionophore A23187 . Proc Natl Acad Sci USA 1979;76:2148-2152.Crossref 4. Brain SD, Camp RDR, Dowd PM, et al: Psoriasis and leukotriene B4 . Lancet 1982;2:762-763.Crossref 5. Brain SD, Camp RDR, Leigh IM, et al: The synthesis of leukotriene B4-like material by cultured human keratinocytes . J Invest Dermatol 1982;78:328. 6. Ford-Hutchinson AW, Bray MA, Doig MV, et al: Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes . Nature 1980;286:264-265.Crossref 7. Goetzl EJ, Pickett WC: The human PMN leukocyte chemotactic activity of complex hydroxy-eicosatetraenoic acids (HETEs) . J Immunol 1980;125:1789-1791. 8. Nagy L, Lee TH, Goetzl EJ, et al: Complement receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase products . Clin Exp Immunol 1982;47:541-547. 9. Carr SC, Couts AA, Greaves MW, et al: Responses of human skin to intradermal injection of leukotrienes C4, D4, and B4 . J Invest Dermatol 1982;78:329. 10. Cashin CH, Dawson W, Kitchen EA: The pharmacology of benoxaprofen (2-[4-chlorophenyl]-α-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with anti-inflammatory activity apparently unrelated to inhibition of prostaglandin synthesis . J Pharm Pharmacol 1977;29:330-336.Crossref 11. Dawson W, Boot JR, Harvey J, et al: The pharmacology of benoxaprofen with particular reference to effects on lipoxygenase product formation . Eur J Rheumatol Inflam 1982;5:61-68. 12. Meacock SCR, Kitchen EA, Dawson W: Effects of benoxaprofen and other non-steroidal anti-inflammatory drugs on leukocyte migration . Eur J Rheumatol Inflam 1979;3:23-28. 13. Mikulaschek WM: An update on long-term efficacy and safety with benoxaprofen . Eur J Rheumatol Inflam 1982;5:206-215. 14. Hamdy RC, Mumane B, Pesera N, et al: The pharmacokinetics of benoxaprofen in elderly subjects . Eur J Rheumatol Inflam 1982;5:69-75. 15. Halsey JP, Cardoe N: Benoxaprofen: Side-effect profile in 300 patients . Br Med J 1982;284:1365-1368.Crossref 16. Kligman AM, Kaidbey KH: Phototoxicity to benoxaprofen . Eur J Rheumatol Inflam 1982;5:124-137. 17. Ferguson J, Addo HA, McGill PE, et al: A study of benoxaprofen-induced photosensitivity . Br J Dermatol 1982;107:429-442.Crossref 18. Greist MC, Ozols II, Ridolfo AS, et al: The phototoxic effects of benoxaprofen and their management and prevention . Eur J Rheumatol Inflam 1982;5:61-68. 19. Orentbreich N, Harber LC, Tromovitch TA: Photosensitivity and photo-onycholysis due to demthylchlortetracycline . Arch Dermatol 1961;83:730-737.Crossref 20. Taylor AEM, Goff D, Hindson TC: Association between Stevens-Johnson syndrome and benoxaprofen therapy . Br Med J 1981;282:1433.Crossref 21. Fenton DA, English FS: Toxic epidermal necrolysis, leukopenia and thrombocytopenic purpura: A further complication of benoxaprofen therapy . Clin Exp Dermatol 1982;7:277-280.Crossref 22. Essigman WK, Williams FRB: Transient neutropenia due to benoxaprofen . Lancet 1980;2:1383.Crossref 23. Taggart HM, Alderdice FM: Fatal cholestatic jaundice in elderly patients taking benoxaprofen . Br Med J 1982;284:1372.Crossref 24. Lewis RA, Austen KF: Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds . Nature 1981;293:103-108.Crossref 25. Katayama H, Kawada A: Exacerbation of psoriasis induced by indomethacin . J Dermatol 1981;8:323-327. 26. Hammerstrom S, Hamberg M, Duell EA, et al: Glucocorticoid in inflammatory proliferative skin disease reduces arachidonic and hydroxyeicosatetraenoic acids . Science 1977;197:994-996.Crossref 27. Cantiere JS, Graff G, Goldberg ND: Cyclic GMP metabolism in psoriasis: Activation of soluble epidermal guanylate cyclase by arachidonic acid and 12-hydroxy-5,8,10,14-eicosatetraenoic acid . J Invest Dermatol 1980;74:234-237.Crossref 28. Marcelo CL, Duell EA, Stawiski MA, et al: Cyclic nucleotide levels in psoriatic and normal keratomed epidermis . J Invest Dermatol 1979;72:20-24.Crossref 29. Voorhees JJ: Cyclic AMP regulation of normal and psoriatic epidermis . Arch Dermatol 1982;118:869-874.Crossref 30. Jablonska S, Chowaniec O, Bentner EH, et al: Stripping of the stratum corneum in patients with psoriasis: Production of prepinpoint papules and psoriatic lesions . Arch Dermatol 1982;118:652-657.Crossref 31. Whaba A, Cohen HA, Ba-Eli M, et al: Enhanced chemotactic and phagocytic activities of leukocytes in psoriasis vulgaris . J Invest Dermatol 1978;71:186-188.Crossref 32. Krueger GG, Jederberg WW, Ogden BE, et al: Inflammatory and immune cell function in psoriasis: II. Monocyte function, lymphokine production . J Invest Dermatol 1978;71:195-207.Crossref 33. Allen BR, Littlewood SM: Benoxaprofen: Effect on cutaneous lesions in psoriasis . Br Med J 1982;285:1241.Crossref 34. Hindson C, Lawlor F, Wacks H: Treatment of nodular acne with benoxaprofen . Br J Dermatol 1982;107:369-372.Crossref 35. Hindson C, Daymond T, Diffey B, et al: Side effects of benoxaprofen . Br Med J 1982;284:1368-1369.Crossref
Cutaneous Histiocytosis X: The Presence of S-100 Protein and Its Use in DiagnosisRowden, Geoffrey;Connelly, Eileen M.;Winkelmann, Richard K.
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310015003
Abstract • The cellular localization of glial S-100 protein was investigated in paraffin-embedded sections of cutaneous histiocytosis X and in a variety of cutaneous infiltrative disorders, including juvenile xanthogranuloma, necrobiotic xanthogranuloma, papular xanthoma, eruptive histiocytoma, and reticulohistiocytosis. Immunoperoxidase staining with a rabbit anti-calf brain-S-100 antibody demonstrated strong and consistent activity in atypical histiocytes in all histiocytosis X specimens. No detectable S-100 protein was demonstrated in either histiocytes or giant cells in the non-X histiocytic disorders investigated. Positive controls were included within both groups of disorders in respect to melanocyte, epidermal Langerhans' cell, and dermal Schwann's cell staining. These findings are interpreted as evidence for diversity in the mononuclear phagocyte system and demonstrate the practicality of such a simple test in diagnostic problems involving infiltrative histiocytic disorders of the skin. (Arch Dermatol 1983;119:553-559) References 1. Bonvalet D, Civatte J: Histiocytosis histopathology . G Ital Derm Venerol 1980;115:51-58. 2. Winkelmann RK: Adult histiocytic skin disease . G Ital Derm Venerol 1980;115:67-76. 3. Turiaf J, Basset F: Deux nouveaux cas d'histiocytosis X a localisations pulmonaires et osseuses avec presence dans les lesions granulomateuses de particules tubulaires intracytoplasmiques suggerants une structure virale . Bull Soc Med Hosp Paris 1966;117:373-383. 4. Carrington SG, Winkelmann RK: Electron microscopy of histiocytic diseases of the skin . Acta Derm Venerol 1972;52:161-178. 5. Caputo R, Gianotti F: Cytoplasmic markers, ultrastructural features in histiocytic proliferations of the skin . G Ital Derm Venerol 1980;115:107-120. 6. Gianotti F: Cutaneous proliferative histiocytoses in children . G Ital Derm Venerol 1980;115:59-66. 7. Barrow MV, Holubar K: Multicentric reticulohistocytosis: A review of 33 patients . Medicine 1969;48:287-305.Crossref 8. Winkelmann RK: Cutaneous syndromes of non-X histiocytosis: A review of the macrophage-histiocyte diseases of the skin . Arch Dermatol 1981;117:667-672.Crossref 9. Moore BW: Chemistry and biology of two proteins, S-100 and 14-3-2 specific to the nervous system . Int Rev Neurobiol 1972;15:215-225. 10. Stefansson D, Wollmann RL, Moore BW: Distribution of S-100 protein outside the central nervous system . Brain Res 1982;234:309-317.Crossref 11. Cocchia D, Michetti F, Donato R: Immunochemical and immunocytochemical localization of S-100 antigen in normal human skin . Nature 1981;294:85-87.Crossref 12. Sternberger LA, Hardy PH Jr, Cuculis JJ, et al: The unlabeled antibody enzyme method of immunohistochemistry . J Histochem Cytochem 1970;18:315-333.Crossref 13. Pfeiffer SE, Sundarraj H, Dawson G, et al: Human acoustic neuromas: Nervous system specific biochemical parameters . Acta Neuropathol 1979;47:27-31.Crossref 14. Moore BW: A soluble protein characteristic of the nervous system . Biochem Biophys Res Commun 1965;19:739-744.Crossref 15. Levine L, Moore BW: Structural relatedness of a vertebrate brain acidic protein as measured immunochemically . Neurosci Res Program Bull 1965;3:18-23. 16. Isobe H, Okuyama T: The amino acid sequence of S-100 protein (PAP, I-b protein) and its relation to calcium-binding proteins . Eur J Biochem 1978;89:379-388.Crossref 17. Burgdorf WHC, Duray P, Rosai J: Immunohistochemical identification of lysozyme in cutaneous lesions of alleged histiocytic nature . Am J Clin Pathol 1981;75:162-167. 18. Pfeiffer SE, Herschman HR, Lightbody J, et al: Synthesis by a clonal line of rat glial cells of a protein unique to the nervous system . J Cell Physiol 1970;75:329-340.Crossref 19. Veldman JE, Kaiserling E: Interdigitating cells , in Carr I, Daems WT (eds): The Reticuloendothelial System . New York, Plenum Publishing Corp, 1980, vol 1, pp 381-416. 20. Thorbecke GJ, Silberg-Sinakin I, Flotte TJ: Langerhans cells as macrophages in skin and lymphoid organs . J Invest Dermatol 1980;75:32-43.Crossref 21. Muller-Hermelink HK, Schwarting H: Functional studies on histiocytic and interdigitating reticulum cells from human lymphoid tissue . Virchows Arch Cell Pathol 1981;37:217-224.Crossref 22. Drexhage HA, Mullink H, DeGroot J, et al: A study of cells present in peripheral lymph of pigs with special reference to a type of cell resembling the Langerhans cell . Cell Tissue Res 1979;202:407-430.Crossref 23. Spry CJF, Pflug AJ, Janossy G, et al: Large mononuclear (veiled) cells with `Ia-like' membrane antigens in human afferent lymph . Clin Exp Immunol 1980;39:750-755. 24. Mason DW, Pugh CW, Webb M: The rat mixed lymphocyte reaction: Roles of a dendritic cell in intestinal lymph and T-cell subsets defined by monoclonal antibodies . Immunology 1981;44:75-87. 25. Takahashi K, Yamaguchi H, Ishizeki J, et al: Immunohistochemical and immunoelectron microscopic localizations of S-100 protein in the interdigitating cells of the human lymph node . Virchows Arch Cell Pathol 1981;37:125-135.Crossref 26. Lampert IA, Pizzolo G, Thomas A, et al: Immuno-histochemical characterization of cells involved in dermatopathic lymphodenopathy . J Pathol 1980;131:145-156.Crossref 27. Rausch E, Kaiserling E, Goos M: Langerhans cells and IDC in the thymus-dependent region in human dermatopathic lymphadenitis . Virchows Arch Cell Pathol 1977;25:327-343. 28. Steinman RM, Nussenzweig MC: Dendritic cells: Features and functions . Immunol Rev 1980;53:127-147.Crossref 29. Klinkert WEF, Labadie JH, O'Brien JP, et al: Rat dendritic cells function as accessory cells and control the production of a soluble factor required for mitogenic responses of T lymphocytes . Proc Natl Acad Sci USA 1980;77:5414-5418.Crossref 30. Koide Y, Awashima F, Akaza T, et al: Human antigen presenting cells: Characterization of the cells in the T-lymphocyte proliferative response . Microbiol Immunol 1981;25:489-503.Crossref 31. Picker LJ, Raff HV, Goldyne ME, et al: Metabolic heterogeneity among monocytes and its modulation by PGE2 . J Immunol 1980;124:2557-2562. 32. Nussenzweig MC, Steinman RM, Witner MD, et al: A monoclonal antibody specific for mouse dendrite cells . Proc Natl Acad Sci USA 1982;79:161-165.Crossref 33. Flotte TJ, Springer T, Thorbecke GJ: Dendritic cells and macrophage staining by monoclonal antibodies, abstracted . Fed Proc 1982;41:17. 34. Montfort I, Tamayo RP: Two antigenically different types of macrophages . Proc Soc Exp Biol Med 1971;138:204-207.Crossref 35. Ugolini V, Nunez G, Smith RG, et al: Initial characterization of monoclonal antibodies against monocytes . Proc Natl Acad Sci USA 1980;71:6764-6788.Crossref 36. Nezelof C, Diebold N, Rousseau-Merek MF: Ig surface receptors and erythrophagocytic activity in histocytosis X cells in culture . J Pathol 1977;122:105-113.Crossref 37. Daems WT, Koerten HK, Soranzo MR: Differences between monocyte-derived and tissue macrophages, abstracted . Adv Exp Med Biol 1976;73A:27-40. 38. Wing EJ, Gardner JA, Rynning FW, et al: Dissociation of EF factor functions of activated macrophages . Nature 1977;268:642-644.Crossref 39. Turk JL: Immunologic and nonimmunologic activation in macrophages . J Invest Dermatol 1980;74:301-306.Crossref 40. Volkman A: The origin and fate of the monocyte . Sem Hematol 1970;111:62-92. 41. Sawyer RT, Strausbauch PH, Volkman A: Resident macrophage proliferation in mice depleted of blood monocytes by strontium-89 . Lab Invest 1982;46:165-170. 42. Moore BW: Acidic protein , in Lajthe A (ed): Handbook of Neurochemistry . New York, Plenum Publishing Corp, 1969, vol 1, pp 93-99. 43. Bock E: Nervous system specific proteins . J Neurochem 1978;30:7-14.Crossref 44. Varon SS, Somjen GG: Neuron-glial interactions . Neurosci Res Program Bull 1979;17:1-238. 45. Lechler RI, Batchelor JR: Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells . J Exp Med 1982;155:31-41.Crossref
Anticentromere and Anticentriole Antibodies in the Scleroderma SpectrumTuffanelli, Denny L.;McKeon, Frank;Kleinsmith, D'Anne M.;Burnham, Thomas K.;Kirschner, Marc
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310022004
Abstract • We studied serum samples from 106 patients, including 80 in the scleroderma spectrum, by indirect immunofluorescent microscopy, using PtK, rat kangaroo tissue culture cells as substrate. Anticentromere (Kinetochore) antibodies were present in 28 patients, and anticentriole antibodies were present in four patients. Anticentromere antibodies were usually present in patients with a benign, chronic form of systemic scleroderma, which has been termed the CREST (Calcinosis, Raynaud's phenomenon, esophageal involvement, sclerodactyly, and telangiectasia) syndrome. The four patients with a previously undescribed anticentriole antibody were all in the scleroderma spectrum. Possibly, these antibodies may have diagnostic and prognostic importance. Further, they will be useful in studying the structure and function of these cellular organelles. (Arch Dermatol 1983;119:560-566) References 1. Swanson Beck J, Anderson JR, Gray KG, et al: Antinuclear and precipitating autoantibodies in progressive systemic sclerosis . Lancet 1963;2:1188-1190.Crossref 2. Burnham TK, Fine G, Neblett TR: The immunofluorescent tumor imprint technique: II. The frequency of antinuclear factors in connective tissue diseases and dermatoses . Ann Intern Med 1966;65:9-19.Crossref 3. Rothfield NF, Rodnan GP: Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma) . Arthritis Rheum 1968;11:607-617.Crossref 4. McGiven AR, de Boer WGRM, Barnett AJ, et al: Autoantibodies in scleroderma . Med J Aust 1968;2:533-536. 5. Burnham TK, Neblett TR, Fine G: The immunofluorescent tumor imprint technic: III. The diagnostic and prognostic significance of the `speckle' inducing antinuclear antibody . Am J Clin Pathol 1968;50:683-688. 6. Tan EM, Rodnan GP, Garcia I, et al: Diversity of antinuclear antibodies in progressive systemic sclerosis . Arthritis Rheum 1980;23:617-625.Crossref 7. Burnham TK, Bank PW: Antinuclear antibodies: I. Patterns of nuclear immunofluorescence . J Invest Dermatol 1974;62:526-534.Crossref 8. Burnham TK: Antinuclear antibodies: A simplified classification of the nuclear immunofluorescent patterns . Arch Dermatol 1978;114:1343-1344.Crossref 9. Pinnas JL, Northway JD, Tan EM: Antinucleolar antibodies in human sera . J Immunol 1973;111:996-1004. 10. Tan EM, Rodnan GP: Profile of antinuclear antibodies in progressive systemic sclerosis (PSS), abstracted . Arthritis Rheum 1975;18:430. 11. Moroi Y, Peebles C, Fritzler MJ, et al: Autoantibody to centromere (kinetochore) in scleroderma sera . Proc Natl Acad Sci USA 1980;77:1627-1631.Crossref 12. Tuffanelli D, McKeon F, Kirschner M: Persistent anti-kinetochore (centromere) and anti-centriole antibodies in scleroderma and Raynaud's disease, abstracted . Clin Res 1982;30:612. 13. Thiebierge G, Weissenbach RJ: Concrétions calcaires souscutanées et sclérodermie . Ann Dermatol Venereol 1911;42:129-155. 14. Sellei J: Die akrosklerosis (sklerodaktylie) und deren symptomenkomplex nebst neueren untersuchungen bei sklerodermie . Arch Dermatol Syphil 1911;163:343-350.Crossref 15. O'Leary PA, Waisman M: Acrosclerosis . Mayo Clin Proc 1940;15:702-707. 16. Kay DM, Tuffanelli DL: Immunofluorescent technique in clinical diagnosis of cutaneous disease . Ann Intern Med 1969;71:753-762.Crossref 17. Miyachi K, Tan EM: Antibodies reacting with ribosomal ribonucleoprotein in connective tissue diseases . Arthritis Rheum 1979;22:87-93.Crossref 18. Nakamura RM, Tan EM: Recent progress in the study of autoantibodies to nuclear antigens . Hum Pathol 1978;9:85-91.Crossref 19. Parker MD, Kerby GP: Combined titre and fluorescent pattern of IgG antinuclear antibodies using cultured cell monolayers in evaluating connective tissue diseases . Ann Rheum Dis 1974;33:465-472.Crossref 20. Turksen K, Aubin JE, Kalnins VI: Identification of a centriole-associated protein by antibodies present in normal rabbit sera . Nature 1982;298:763-764.Crossref 21. McCarty GA, Valencia DW, Fritzler MJ, et al: A unique antinuclear antibody staining only the mitotic-spindle apparatus . N Engl J Med 1981;305:703.Crossref 22. Khan MM, Tan EM: Autoantibodies to a nuclear polypeptide in the sera of patients with scleroderma, abstracted . Arthritis Rheum 1982;25:530. 23. Prystowsky SD, Gilliam JN, Tuffanelli DL: Epidermal nucleolar IgG deposition in clinically normal skin . Arch Dermatol 1978;114:536-538.Crossref 24. Kleinsmith DM, Heinzerling RH, Burnham TK: Antinuclear antibodies as immunologic markers for a benign subset and different clinical characteristics of scleroderma . Arch Dermatol 1982;118:882-885.Crossref 25. Fritzler MJ, Kinsella TD: The CREST syndrome: A distinct serologic entity with anticentromere antibodies . Am J Med 1980;69:520-526.Crossref 26. Steen V, Ziegler GL, Rodnan GP, et al: Clinical associations of anticentromere antibodies in patients with progressive systemic sclerosis, abstracted . Arthritis Rheum 1982;25:54. 27. Bernstein RM, Callender ME, Neuberger JM, et al: Antinuclear antibodies in primary biliary cirrhosis, abstracted . Arthritis Rheum 1982;25:5109. 28. Moroi Y, Hartman AL, Nakane PK, et al: Distribution of kinetochore (centromere) antigen in mammalian cell nuclei . J Cell Biol 1981;90:254-259.Crossref
Pigmentation of Open Comedones: An Ultrastructural StudyZelickson, Alvin S.;Mottaz, Jess H.
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310029005
Abstract • Ultrastructural examination of expressed "black" open comedones did not disclose any single melanosomes or melanosome complexes. If there is any melanin present in comedonal plugs, the amount is minimal, and it cannot be the source of the black color. (Arch Dermatol 1983;119:567-569) References 1. Blair C, Lewis CA: The pigment of comedones . Br J Dermatol 1970;82:572-582.Crossref 2. Goodhead DT: Electron spin resonance of melanin in comedones . Br J Dermatol 1970;83:182-188.Crossref 3. Kaidbey KH, Kligman AM: Pigmentation in comedones . Arch Dermatol 1974;109:60-62.Crossref
Patient Concepts and Misconceptions About AcneRasmussen, James E.;Smith, Steven B.
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310032006
Abstract • A questionnaire was completed by 178 patients and relatives with dermatologic conditions as the first phase of a two-part study of the interrelationships between understanding and treatment compliance. Substantial numbers of those surveyed had ideas about cause, treatment, and prognosis that might adversely affect therapy. Diet, dirt, soap and water, topically applied acne gels, and realistic expectations for cures seem to be the most important subjects to emphasize in the written or oral "teaching" of patients with acne. (Arch Dermatol 1983;119:570-572) References 1. Anderson PC: Foods as the cause of acne . Am J Fam Pract 1971;3:102-103. 2. Fulton JE, Plewig G, Kligman AM: Effect of chocolate on acne vulgaris . JAMA 1969;210:2071-2073.Crossref 3. Rasmussen JE: Diet and acne . Dermatologica 1977;16:488-492. 4. Emerson GW, Strauss JS: Acne and acne care: A trend survey . Arch Dermatol 1972;105:407-411.Crossref 5. Plewig G, Fulton JE, Kligman AM: Pomade acne . Arch Dermatol 1960;101:580-583.Crossref 6. Kligman AM, Mills OH Jr: Acne cosmetica . Arch Dermatol 1972;106:843-846.Crossref 7. Weintraub M: Promoting patient compliance . NY State J Med 1975;75:2263-2266. 8. Moser RH: Sounding board: Knowledge is not enough . N Engl J Med 1977;296:938-940.Crossref 9. Becker MH: Patient compliance . J Med Educ 1973;48:966-967.
Granuloma Faciale: Treatment With the Argon LaserApfelberg, David B.;Druker, David;Maser, Morton R.;Lash, Harvey;Spence, Bart;Deneau, David
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310035007
Abstract • Three patients with granuloma faciale were successfully treated by argon laser therapy. The intense blue-green laser light is readily absorbed by these inflammatory lesions, resulting in resolution of the clinical and microscopic abnormalities. There were no recurrences during follow-up periods of 23, 21, and 5 months, respectively. Argon laser therapy appears to be an important addition to the treatment armamentarium for this uncommon, but difficult to treat, entity. (Arch Dermatol 1983;119:573-576) References 1. Arundell FD, Burdick KH: Granuloma faciale treated with intradermal dexamethasone . Arch Dermatol 1960;82:437-441.Crossref 2. Johnson WC, Higdon RS, Helwig EB: Granuloma faciale . Arch Dermatol 1959;79:42-52.Crossref 3. Franks AG, Gordon BI: Diagnosis: Facial granuloma with eosinophils . Arch Dermatol 1960;82:1019-1030. 4. Bergfeld WF, Scholes NT, Roemigk HH: Granuloma faciale: Treatment by dermabrasion . Cleve Clin Q 1970;37:215-217.Crossref 5. Anderson CR: Dapsone in granuloma faciale . Lancet 1975;1:642.Crossref 6. Apfelberg DB, Kosek J, Maser MR, et al: Histology of port wine stains following argon laser treatment . Br J Plast Surg 1979;32:232-237.Crossref 7. Apfelberg DB, Greene RA, Maser MR, et al: Results of argon laser exposure of capillary hemangiomas of infancy: Preliminary report . Plast Reconstr Surg 1981;67:188-193.Crossref 8. Apfelberg DB, Maser MR, Lash H, et al: The argon laser for cutaneous lesions . JAMA 1981;245:2073-2075.Crossref 9. Brown M: Granuloma faciale . Arch Dermatol 1974;110:477-478.Crossref 10. Schroeter AL, Copeman PWM, Jordon RE, et al: Immunofluorescence of cutaneous vasculitis associated with systemic disease . Arch Dermatol 1971;104:254-259.Crossref 11. Pedace FJ, Perry HU: Granuloma faciale . Arch Dermatol 1966;94:387-396.Crossref 12. Lever WF: Histopathology of the Skin . Philadelphia, JB Lippincott Co, 1975, pp 166-167.
Comparative Activity of Benzoyl Peroxide and Hexachlorophene: In Vivo Studies Against Propionibacterium acnes in HumansNacht, Sergio;Gans, Eugene H.;McGinley, Kenneth J.;Kligman, Albert M.
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310039008
Abstract • The bactericidal effects of benzoyl peroxide (5% lotion) and hexachlorophene (3% colloidal suspension) against Propionibacterium acnes were compared in nine healthy college students who had the microbiological and skin lipid characteristics typical of acne vulgaris, but no active lesions. Each of the two medications was applied twice daily, to opposite sides of the face, for four consecutive weeks. Hexachlorophene was effective against surface aerobes but only slightly active against P acnes. It marginally reduced free fatty acid concentrations in surface lipids and in follicular porphyrin fluorescence. Conversely, benzoyl peroxide virtually eliminated P acnes and aerobes and induced substantially decreased free fatty acid concentrations and follicular fluorescence. We conclude that benzoyl peroxide exerts its antimicrobial action in the follicles and inhibits P acnes, while the antimicrobial effectiveness of hexachlorophene is limited to the skin surface. (Arch Dermatol 1983;119:577-579) References 1. Kligman AM, Leyden JE, Stewart R: New uses for benzoyl peroxide: A broad-spectrum antimicrobial agent . Int J Dermatol 1977;16:413-417.Crossref 2. Lyons RE: Comparative effectiveness of benzoyl peroxide and tretinoin in acne vulgaris . Int J Dermatol 1978;17:246-251.Crossref 3. Fulton JE Jr, Farzad-Bakshandeh A, Bradley S : Studies on the mechanism of action of topical benzoyl peroxide and vitamin A acid in acne vulgaris . J Cutan Pathol 1974;1:191-200.Crossref 4. Fulton JE Jr, Bradley S: The choice of vitamin A acid, erythromycin, or benzoyl peroxide for the topical treatment of acne . Cutis 1976;17:560-564. 5. Kligman AM, Mills OH, McGinley KJ, et al: Acne therapy with tretinoin in combination with antibiotics . Acta Derm Venereol 1975;74( (suppl) ):111-115. 6. Anderson AS, Galdys GJ, Green RC, et al: Improved reduction of cutaneous bacteria and free fatty acids with new benzoyl peroxide gel . Cutis 1975;16:307-310. 7. Koda CF, Grubb TC, Alexander JF: In vitro study of antibacterial action of various chemicals on Corynebacterium acnes . J Pharm Sci 1965;54:478-480.Crossref 8. McGinley KJ, Webster GF, Leyden JJ: Facial follicular porphyrin fluorescence: Correlation with age and density of Propionibacterium acnes . Br J Dermatol 1980;102:437-441.Crossref 9. Williamson P, Kligman AM: A new method for the quantitative investigation of cutaneous bacteria . J Invest Dermatol 1965; 45:498-503.Crossref 10. Downing DT: Photodensitometry in the thin layer chromatographic analysis of neutral lipids . J Chromatogr 1968;38:91-99.Crossref 11. Kraning K, Odland GF (eds): Research needs in 11 major areas in dermatology: III . Acne. J Invest Dermatol 1979;73(part (2) ):434-442.Crossref 12. Martin RJ, Kahn G, Gooding JW, et al: Cutaneous porphyrin fluorescence as an indicator of antibiotic absorption and effectiveness . Cutis 1973;12:758-764. 13. Marples RR, Downing DT, Kligman AM, et al: Control of free fatty acids in human surface lipids by Corynebacterium acnes . J Invest Dermatol 1971;56:127-131.Crossref 14. Hurwitz S: The combined effect of vitamin A acid and benzoyl peroxide in the treatment of acne . Cutis 1976;17:585-590. 15. Nacht S, Yeung D, Beasley J, et al: Benzoyl peroxide: Percutaneous penetration and metabolic disposition . J Am Acad Dermatol 1981;4:31-37.Crossref
Late-Onset Chronic Mucocutaneous and Ocular Candidiasis and Malignant ThymomaPalestine, Roberta F.;Su, W. P. Daniel;Liesegang, Thomas J.
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310042009
Abstract • Late-onset chronic mucocutaneous candidiasis (CMCC) is part of a spectrum of candidal infections. It usually develops during or after the fourth decade of life and is often associated with an underlying neoplasm, especially thymoma. A 56-year-old man with late-onset CMCC and thymoma had several unusual features. His malignant thymoma seemed to be more widespread than the thymomas of previously described patients. Ocular infection was present in addition to extensive involvement of the skin, nails, and oral mucosa. To our knowledge, this is the first report of ocular involvement in this syndrome. We also believe that this is the first patient with thymoma-associated late-onset CMCC to be treated effectively with ketoconazole. (Arch Dermatol 1983;119:580-586) References 1. Maize JC, Lynch PJ: Chronic mucocutaneous candidiasis of the adult: A report of a patient with an associated thymoma . Arch Dermatol 1972;105:96-98.Crossref 2. Kirkpatrick CH, Windhorst DB: Mucocutaneous candidiasis and thymoma . Am J Med 1979;66:939-945.Crossref 3. Becker SW, Kahn D, Rothman S: Cutaneous manifestations of internal malignant tumors . Arch Dermatol 1942;45:1069-1080.Crossref 4. Rothman S: Some unusual forms of cutaneous moniliasis, abstracted . Arch Dermatol 1959;79:598-600.Crossref 5. Engman MF, Weiss RS: Monilia candida infection of the mouth: Moeller's disease, pneumococcus infection of the tongue, etc . Arch Dermatol 1920;1:119-136. 6. Aronson IK, Rieger CHL, Soltani K, et al: Late onset chronic mucocutaneous candidiasis with lymphoma and specific serum inhibitory factor . Cancer 1979;43:101-108.Crossref 7. Higgs JM, Wells RS: Chronic muco-cutaneous candidiasis: New approaches to treatment . Br J Dermatol 1973;89:179-190.Crossref 8. Aronson IK, Soltani K: Chronic mucocutaneous candidosis: A review . Mycopathologia 1976;60:17-25.Crossref 9. Martin CM, Gordon RS, McCullough NB: Acquired hypogammaglobulinemia in an adult: Report of a case, with clinical and experimental studies . N Engl J Med 1956;254:449-456.Crossref 10. Josse JW, Zacks SI: Thymoma and pancytopenia: Report of a case and review of the literature . N Engl J Med 1958;259:113-117.Crossref 11. Green RA, Booth CB: The development of myasthenia gravis after removal of thymoma . Am J Med 1958;25:293-302.Crossref 12. Gafni J, Michaeli D, Heller H: Idiopathic acquired agammaglobulinemia associated with thymoma: Report of two cases and review of the literature . N Engl J Med 1960;263:536-541.Crossref 13. Anning ST: Myasthenia gravis and candidiasis, abstracted . Br J Dermatol 1962;74:106-107. 14. Baer RL, Bart RS, Stritzler R, et al: Exfoliative Erythrodermie und Thymom: Gleichzeitiges Vorkommen einer ungewöhnlichen generalisierten Dermatose, "universeller" cutaner Candidiasis und eines Thymoms: Bericht eines Falles . Hautarzt 1964;15:413-418. 15. Montes LF, Carter RE, Moreland N, et al: Generalized cutaneous candidiasis associated with diffuse myopathy and thymoma . JAMA 1968;204:351-354.Crossref 16. Calnan CD: Chronic mucocutaneous candidiasis, abstracted . Br J Dermatol 1970;83:423-424. 17. Schoch EP Jr: Thymic conversion of Candida albicans from commensalism to pathogenism . Arch Dermatol 1971;103:311-318.Crossref 18. Montes LF, Ceballos R, Cooper MD, et al: Chronic mucocutaneous candidiasis, myositis, and thymoma: A new triad . JAMA 1972;222:1619-1623.Crossref 19. Higgs JM, Wells RS: Klassifizierung der chronischen mucocutanen Candidiasis mit Betrachtungen zum klinischen Bild und zur Therapie . Hautarzt 1974;25:159-165. 20. Twomey JJ, Waddell CC, Krantz S, et al: Chronic mucocutaneous candidiasis with macrophage dysfunction, a plasma inhibitor, and co-existent aplastic anemia . J Lab Clin Med 1975;85:968-977. 21. Windhorst DB, Stoltzner G: Candidiasis in thymoma . Sci Publ Pan Am Health Organization 1975;304:42-47. 22. Rycroft RJG, Valdimarsson H, Bannister LH, et al: Chronic muco-cutaneous candidiasis of late onset, thymoma and myopathy: A report of four cases . Clin Exp Dermatol 1976;1:59-74.Crossref 23. Mobacken H, Lindholm L, Olling S: Deficient neutrophil function in a patient with chronic mucocutaneus candidiasis, thymoma and myasthenia gravis . Acta Derm Venereol 1977; 57:335-339. 24. Robins-Browne RM, Green R, Katz J, et al: Thymoma, pure red cell aplasia, pernicious anaemia and candidiasis: A defect in immunohomeostasis . Br J Haematol 1977;36:5-13.Crossref 25. Gatenby P, Basten A, Adams E: Thymoma and late onset mucocutaneous candidiasis associated with a plasma inhibitor of cell-mediated immune function . J Clin Lab Immunol 1980;3:209-216. 26. Kirkpatrick CH, Rich RR, Bennett JE: Chronic mucocutaneous candidiasis: Model-building in cellular immunity . Ann Intern Med 1971;74:955-978.Crossref 27. Roberts SOB, Mackenzie DWR: Mycology , in Rook AJ, Wilkinson DS, Ebling FJG (eds): Textbook of Dermatology , ed 3. Oxford, England, Blackwell Scientific Publications, 1979, vol 1, p 841. 28. Gass JDM: The syndrome of keratoconjunctivitis, superficial moniliasis, idiopathic hypoparathyroidism and Addison's disease . Am J Ophthalmol 1962;54:660-674. 29. Hermans PE, Ulrich JA, Markowitz H: Chronic mucocutaneous candidiasis as a surface expression of deep-seated abnormalities: Report of a syndrome of superficial candidiasis, absence of delayed hypersensitivity and aminoaciduria . Am J Med 1969;47:503-519.Crossref 30. Lehner T: Classification and clinico-pathological features of candida infections in the mouth , in Winner HI, Hurley R (eds): Symposium on Candida Infections . Edinburgh, E & S Livingstone, 1966, pp 119-136. 31. Wuepper KD, Fudenberg HH: Moniliasis, `autoimmune' polyendocrinopathy, and immunologic family study . Clin Exp Immunol 1967;2:71-82. 32. Chappler RR, Maibach HI, Conant MA, et al: Mucocutaneous candidiasis or mucocutaneous microbiosis ? JAMA 1978; 239:428-429.Crossref 33. Souadjian JV, Enriquez P, Silverstein MN, et al: The spectrum of diseases associated with thymoma: Coincidence or syndrome ? Arch Intern Med 1974;134:374-379.Crossref 34. Edwards JE Jr, Lehrer RI, Stiehn ER, et al: Severe candidal infections: Clinical perspective, immune defense mechanisms, and current concepts of therapy . Ann Intern Med 1978;89:91-106.Crossref 35. Sohnle PG, Frank MM, Kirkpatrick CH: Deposition of complement components in the cutaneous lesions of chronic mucocutaneous candidiasis . Clin Immunol Immunopathol 1976; 5:340-350.Crossref 36. Petersen EA, Alling DW, Kirkpatrick CH: Treatment of chronic mucocutaneous candidiasis with ketoconazole: A controlled clinical trial . Ann Intern Med 1980;93:791-795.Crossref 37. Graybill JR, Herndon JH Jr, Kniker WT, et al: Ketoconazole treatment of chronic mucocutaneous candidiasis . Arch Dermatol 1980;116:1137-1141.Crossref
Metastasizing Basal Cell Carcinoma Originating in a Stasis Ulcer in a Black WomanLanehart, William H.;Sanusi, Irwan D.;Misra, Raghunath P.;O'Neal, Barron
1983 Archives of Dermatology
doi: 10.1001/archderm.1983.01650310049010
Abstract • A case of basal cell carcinoma originated in a long-standing stasis ulcer on the lower extremity and then metastasized to the dermis and subcutaneous tissue of the thigh. The literature on metastasizing basal cell carcinoma is reviewed. (Arch Dermatol 1983;119:587-591) References 1. Wermuth BM, Fajardo LF: Metastatic basal cell carcinoma: A review . Arch Pathol Lab Med 1970;90:458-462. 2. Matsuoka LY, Schauer PK, Sordillo PP: Basal cell carcinoma in black patients . J Am Acad Dermatol 1981;4:670-672.Crossref 3. Fleming ID, Barnawell JR, Burlison PE, et al: Skin cancer in black patients . Cancer 1975;35:600-605.Crossref 4. Mora RG, Burris R: Cancer of the skin in blacks: A review of 128 patients with basal cell carcinoma . Cancer 1981;47:1436-1438.Crossref 5. Pascher F, Sims CF: Basal cell epitheliomas of the sole: A report of two cases . Arch Dermatol 1954;69:475-481. 6. Burns DA, Calnan CD: Basal cell epithelioma in a chronic leg ulcer . Clin Exp Dermatol 1978;3:443-445.Crossref 7. Tenopyr J, Silverman I: The relation of chronic varicose ulcer to epithelioma . Ann Surg 1932;95:754-758.Crossref 8. Mikhail GR, Nims LP, Kelly AP Jr, et al: Metastatic basal cell carcinoma: Review, pathogenesis, and report of two cases . Arch Dermatol 1977;113:1261-1269.Crossref 9. Knox LC: Epithelioma and the chronic varicose ulcer . JAMA 1925;85:1046-1051.Crossref 10. Taylor GW, Nathanson IT, Shaw DT: Epidermoid carcinoma of the extremities with reference to lymph node involvement . Ann Surg 1941;113:268-275.Crossref 11. Cruickshank AH, McConnell EM, Miller DG: Malignancy, scars, chronic ulcers and sinuses . J Clin Pathol 1963;16:573-580.Crossref 12. Bowers RF, Young JM: Carcinoma arising in scars, osteomyelitis and fistulae . Arch Surg 1960;80:564-570.Crossref 13. Coburn RJ: Malignant ulcers following trauma , in Andrade R, Gumport SL, Popkin GL, et al (eds): Cancer of the Skin: Biology-Diagnosis-Management . Philadelphia, WB Saunders Co, 1976, vol 1, pp 939-949. 14. Liddell K: Malignant change in chronic varicose ulceration . Practitioner 1975;215:335-339. 15. Black W: Neoplastic disease occurring in varicose ulcers or eczema: A report of six cases . Br J Cancer 1952;6:120-126.Crossref 16. Itayemi SO, Abioye AA, Ogan O, et al: Aggressive basal cell carcinoma in Nigerians . Br J Dermatol 1979;101:465-468.Crossref 17. Safai B, Good RA: Basal cell carcinoma with metastasis: Review of literature . Arch Pathol Lab Med 1977;101:327-331. 18. Scanlon EF, Volkmer DD, Oviedo MA, et al: Metastatic basal cell carcinoma . J Surg Oncol 1980;15:171-180.Crossref 19. Conway H, Hugh NE: Metastatic basal cell carcinoma . Am J Surg 1965;110:620-624.Crossref 20. Stell J, Moyer DG, Dehne R: Basal cell epithelioma metastatic to bone . Arch Dermatol 1966;93:338-340.Crossref 21. Liu P, McGregor F, Chihak R, et al: Basal cell carcinoma with pulmonary metastases . Hiroshima J Med Sci 1971;20:281-289. 22. Hughes JM: Metastatic basal cell carcinoma: A review of two cases and a review of literature . Clin Radiol 1973;24:392-393.Crossref 23. Lattes R, Kessler RW: Metastasizing basal-cell epithelioma of the skin: Report of two cases . Cancer 1951;4:866-878.Crossref 24. Cotran RS: Metastasizing basal cell carcinomas . Cancer 1961;14:1036-1040.Crossref 25. Binkley GW, Rauschkolb RR: Basal-cell epithelioma metastasizing to lymph nodes . Arch Dermatol 1962;86:332-335.Crossref 26. Cade S: Malignant Disease and Its Treatment by Radium . Baltimore, Williams & Wilkins Co, 1952, vol 4, pp 7-8. 27. Paver K, Poyzen K, Burry N, et al: The incidence of basal cell carcinomas and their metastases in Australia and New Zealand . Australas J Dermatol 1973;14:53.Crossref 28. Pinkus H: The borderline between cancer and non-cancer: Interrelationships between stroma and epithelium , in Andrade R, Gumport SL, Popkin GL, et al (eds): Cancer of the Skin: BiologyDiagnosis-Management . Philadelphia, WB Saunders Co, 1976, vol 1, pp 386-404. 29. Fawcett AN, Harrison DA: Two unusual leg ulcers . Br J Surg 1972;59:478-481.Crossref 30. Rubenfeld S: Epithelioma developing on a varicose ulcer . Am J Surg 1934;26:372-373.Crossref 31. Dawson EK, McIntosh D: Granulation tissue sarcoma following long-standing varicose ulceration . J R Coll Surg Edinb 1971;16:88-95.